Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Ulcerative Colitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Treating Children’s Health in a Special Needs Pediatric Practice - Brian Udell, MD (2021 Conference) (LDN, low dose naltrexone)

Strategies for reducing excess body fat... - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Reclaim the Lives of Lupus Patients, A Unique Treatment Approach - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

PTSD and other mental health treatment with opioid antagonist... - Galyn Forster, MS, LPC (2021 Conference) (LDN, low dose naltrexone)

Lyme Disease - Darin Ingels, ND (2021 Conference) (LDN, low dose naltrexone)

Henoch-Schonlein Purpura - Sally Daughtrey, ND (2021 Conference) (LDN, low dose naltrexone)

In her presentation, Dr. Daughtry explains Henoch-Schonlein (HSP), its triggers and complications (such as serious hidden infections often missed initially), and the use of Low Dose Naltrexone in treating HSP. Dr. Daughtry gives an in-depth look into one pediatric case she treated successfully with LDN.

Eosinophilic Esophagitis Is More Treatable Than You Think - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)